TACE Clinical Trials

17 clinical trials for TACE across international registries, including 8 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• H101 Plus TACE for r/m HNSCC — RECRUITING · PHASE2
• A Multicenter Prospective Study on the Performance of Spectral CT for Evaluating Treatment Response After TACE in Hepatocellular Carcinoma — RECRUITING
• Construction and Clinical Validation of a Predictive Model for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma Based on Whole-Slide Digital Pathological Images and Deep Learning — RECRUITING · NA
• OE MRI to Predict Treatment Response After TACE in HCC Patients — RECRUITING · NA
• DEB-TACE vs cTACE in HCC After TIPS — RECRUITING · PHASE3
• Adjuvant Radiotherapy of Sintilimab Versus TACE for HCC — RECRUITING · PHASE3
• Lenvatinib Combined with Tislelizumab and TACE Applied As Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma with High-risk Recurrence Factors — RECRUITING · PHASE2
• Single Arm, Prospective, Multicenter Clinical Study of TACE With Adebrelimab and Bevacizumab for Unresectable Hepatocellular Carcinoma — RECRUITING · PHASE2
• Partial Immune-boost TACE in unrEseCTable HCC Patients Under Systemic Treatment — NOT_YET_RECRUITING · PHASE2
• HAIC vs. TACE Combined With ICIs and TKIs in Intermediate-to-Advanced HCC: A Multicenter Study on Liver Injury and Survival — COMPLETED
• Sequential TACE-SBRT Combined With Targeted Immunotherapy for Patients With Intermediate to Advanced Liver Cancer — ACTIVE_NOT_RECRUITING
• A Single-Arm, Multicenter, Exploratory Clinical Study of Transarterial Chemoembolization (TACE) Combined With Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC) — NOT_YET_RECRUITING · PHASE2
• Prediction and Prognostic Analysis of Liver Abscess Formation After Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma (CHANCE 2407) — OTHER
• Clinical Study of the Efficacy and Safety of Transhepatic Arterial Chemoembolization Combined With Tislelizumab and Lenvatinib in Patients With Advanced Unresectable Hepatocellular Carcinoma — OTHER · PHASE1
• Anlotinib Combined With TACE in Hepatocellular Carcinoma Patients at High Risk of Post Surgery Recurrence — OTHER · PHASE2
• Rg3 in Combination With TACE in Hepatocellular Carcinoma Patients With High Expression of Notch1 — COMPLETED · NA
• Radiofrequency Ablation Combined With Transcatheter Arterial Chemoembolization Versus Radiofrequency Ablation Alone for Recurrent Hepatocellular Carcinoma — OTHER · PHASE4

Refine this search